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The new genetics of autism: from rare syndromes to translational opportunities 
 
Richards and colleagues1 have made a useful contribution to our understanding of the 
prevalence of autism spectrum disorder (ASD) in genetic and metabolic syndromes.  
Their meta-analysis demonstrates that the prevalence rates of ASD in these 
syndromes range from high (11% in individuals with 22q11.2 deletion syndrome) to 
very high (36% in tuberous sclerosis complex) to exceedingly high (61% in Rett 
syndrome).  This is against a general population prevalence of around 1%.  The 
findings are of clinical relevance and speak to the ‘new genetics’ of ASD that are 
unveiling clues to the aetiology of the disorder and hold the potential for translational 
discovery to develop and test new interventions2. 
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Clinically, the high rates of ASD in these syndromes support the revisions to the 
DSM-5 diagnostic classification system where the ‘clinical specifiers’ that should be 
noted alongside an ASD diagnosis include ‘known medical or genetic conditions’3.  
The authors highlight that the recognition of an ASD presentation alongside the 
genetic/metabolic syndrome will have important implications for management, for 
example in terms of managing repetitive and rigid behaviours or taking account of 
impairments in social understanding and communicative functioning.  One caveat that 
should be added to the conclusions of the authors is that alongside intellectual 
disability (ID) – another clinical specifier in DSM-5 – it is also the case that other 
common neurodevelopmental and neuropsychiatric conditions (e.g. attention deficit 
hyperactivity disorder (ADHD), anxiety disorders) that are associated both with ASD 
and with ID may also be common in these individuals with these syndrome with 
implications for management4.  As the Richards et al. recognise, there are significant 
challenges to the measurement and establishment (and treatment) of both ASD and 
other associated disorders in individuals with significant ID and the field needs to 
continue to develop clinically useful solutions to such challenges, as they may offer 
tractable pathways to better management and treatment. 
 
In basic and translational science terms, the possibility of reconciling our 
understanding of how single gene disruptions affect neurodevelopment both before 
and after birth – essentially a ‘bottom-up’ approach to revealing mechanisms of 
aetiology – with ‘top-down’ approaches such as searching for the genetic substrate of 
‘idiopathic’ ASD where there is no known genetic anomaly reflects the crossroads at 
which the science of ASD has arrived.  The fact that most genetic and genomic 
disorders show both variable expression and pleitropy5 raises the question of the 
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extent to which the association the authors describe between genetic/metabolic 
syndromes and ASD is specific, or whether such syndromes are associated with more 
general neurodevelopmental disruption that results in behavioural phenotypes that 
include features of ASD, ADHD and ID. 
 
Recent attempts to establish greater specificity between the behavioural phenotype of 
ASD – such as IQ and symptom profiles – and specific genetic substrate have proved 
more challenging than many hoped6.  Whilst single gene disorders may have high 
penetrance in terms of being strongly associated with an ASD phenotype in 
individuals with such mutations – as clearly demonstrated in this article – most 
genetic risk for the broader population of individuals with ASD resides in common 
genetic variation7.  It is also well established that de novo mutations – copy number 
variations (CNVs) – are also associated with the ASD phenotype8.  CNVs that result 
in loss of function may be more strongly associated with ASD in combination with 
significant ID, whereas in individuals with ASD with higher IQs inherited genetic 
influences – as evidenced by higher rates of psychiatric disorders in family members 
– might play a more major role9.  
 
A final consideration of the translational potential of better understanding how genetic 
and metabolic syndromes contribute to the ASD phenotype and commonly associated 
phenotypes is the possibility that such discoveries will offer therapeutic opportunities 
at a neural systems level.  One area of focus that has been strongly influenced by 
recent findings from the study of syndromic forms of ASD are the neural pathways 
involved in synaptic development and functioning10.  There is accumulating evidence 
that these pathways might also be involved in the pathogenesis of nonsyndromic 
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forms of ASD.  After promising findings from preclinical studies within model 
systems and in human neuronal models, pilot trials have begun to test whether a 
number of compounds may have therapeutic potential in human patients.  Promising 
targets including mGluR5 antagonists in fragile X syndrome, mTOR inhibitors in 
tuberous sclerosis and insulin-like growth factor in Phelan-McDermid syndrome11.  If 
these studies are successful then trials will begin with these compounds in 
nonsyndromic or ‘idiopathic’ patients with ASD. 
 
Richards and colleagues have provided a state-of-the-art meta-analytic review that 
reinforces how commonly the ASD and other associated phenotypes are associated 
with rare genetic and metabolic syndromes.  The challenge for clinicians and 
scientists in the years ahead is to further develop clinical practice and translational 
science to put this knowledge to good use for these individuals and those who care for 
them. 
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